Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling.
Left ventricular hypertrophy (LVH) is a crucial attribute of hypertensive coronary heart illness. Renin-angiotensin system (RAS) blockers have been proven to be efficient medication for the reversal of LVH. Clinical and experimental research have proven that Zi Shen Huo Luo Formula (ZSHLF) can enhance the efficacy of perindopril in the therapy of hypertensive LVH, however
Read More